- Report
- March 2025
- 187 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- February 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- February 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- February 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- April 2023
- 175 Pages
Global
From €5511EUR$5,899USD£4,662GBP
- Report
- January 2024
- 200 Pages
Global
From €3877EUR$4,150USD£3,280GBP
- Report
- February 2024
- 73 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
Sulfamethoxazole is an antibiotic drug used to treat a variety of bacterial infections. It is a sulfonamide, a type of synthetic antibacterial agent that is derived from para-aminobenzoic acid. It is used to treat urinary tract infections, bronchitis, and other respiratory infections, as well as some skin and soft tissue infections. It is also used to prevent and treat certain types of pneumocystis pneumonia in people with weakened immune systems. Sulfamethoxazole is often used in combination with trimethoprim, another antibiotic, to treat a variety of infections.
Sulfamethoxazole is available in both generic and brand-name forms. It is available as a tablet, an oral suspension, and an intravenous injection. It is also available in combination with other antibiotics, such as trimethoprim, to treat certain infections.
The sulfamethoxazole market is highly competitive, with many companies offering generic and brand-name versions of the drug. Some of the major companies in the market include Pfizer, Merck, GlaxoSmithKline, Novartis, Sanofi, and Teva Pharmaceuticals. Show Less Read more